Halozyme expects $1. 86B-$1. 925B 2026 revenue while raising non-GAAP EPS to $8. 75-$9. 05

The development centers on halozyme expects $1.86B-$1.925B 2026 revenue while raising non-GAAP EPS to $8.75-$9.05.